Noninfectious Acute Lung Injury Syndromes Early After Hematopoietic Stem Cell Transplantation

Ahya, Vivek N.

doi:10.1016/j.ccm.2017.07.002

Cited by 35 publications

(39 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diffuse alveolar haemorrhage (DAH) is a distinct subtype of IPS defined as BAL showing any of the following [45]: progressively bloodier return on serial lavages, ⩾20% haemosiderin-laden macrophages or blood in at least 30% of alveolar surfaces [46]. It is characterised by rapid progression to respiratory failure [47]. DAH is considered more as a sign of underlying lung injury influenced by multiple risk factors than a distinct disease by itself [48].…”

Section: Diffuse Alveolar Haemorrhagementioning

confidence: 99%

“…DAH is considered more as a sign of underlying lung injury influenced by multiple risk factors than a distinct disease by itself [48]. Risk factors for DAH are multifactorial influenced by graft source (umbilical cord-blood source), higher dose/ myeloablative total body irradiation (TBI) regimen, increased age, delayed neutrophil/ platelet engraftment or primary graft failure [26,[47][48].…”

Section: Diffuse Alveolar Haemorrhagementioning

confidence: 99%

See 1 more Smart Citation

Noninfectious pulmonary complications of haematopoietic stem cell transplantation

2020

View full text Add to dashboard Cite

Haematopoietic stem cell transplantation (HSCT) is an established treatment for a variety of malignant and nonmalignant conditions. Pulmonary complications, both infectious and noninfectious, are a major cause of morbidity and mortality in patients who undergo HSCT. Recent advances in prophylaxis and treatment of infectious complications has increased the significance of noninfectious pulmonary conditions. Acute lung injury associated with idiopathic pneumonia syndrome remains a major acute complication with high morbidity and mortality. On the other hand, bronchiolitis obliterans syndrome is the most challenging chronic pulmonary complication facing clinicians who are taking care of allogeneic HSCT recipients. Other noninfectious pulmonary complications following HSCT are less frequent. This review provides a clinical update of the incidence, risk factors, pathogenesis, clinical characteristics and management of the main noninfectious pulmonary complications following HSCT.

show abstract

Section: Diffuse Alveolar Haemorrhagementioning

confidence: 99%

Section: Diffuse Alveolar Haemorrhagementioning

confidence: 99%

Noninfectious pulmonary complications of haematopoietic stem cell transplantation

2020

View full text Add to dashboard Cite

show abstract

“…Additionally, there is a complex interplay of differential diagnosis, including PERDS and hyperacute GVHD, which have similar timing, symptoms and pathophysiology. The distinction of these from ES is unclear and may manifest from ES, overlap or occur in isolation 11,20,21 . This literature review gathered information from an extensive list of original studies to explore and collate current knowledge to seek consensus or overall best practice recommendations relating to treatment and diagnosis of ES.…”

Section: Discussionmentioning

confidence: 99%

“…Peri‐engraftment respiratory distress syndrome (PERDS) is an emerging term within the literature and may be discussed in connection to ES. However, the link between the two syndromes remains elusive with PERDS potentially being a respiratory manifestation of ES or they may be two distinct entities 19‐22 . PERDS will not be discussed in this paper.…”

Section: Introductionmentioning

confidence: 99%

Engraftment syndrome following hematopoietic stem cell transplant: A review of the literature

Grant

Chapman

Mitchell

et al. 2020

Clinical Transplantation

View full text Add to dashboard Cite

Engraftment syndrome (ES) is a poorly understood condition which continues to present a significant cause of morbidity following haematopoietic stem cell transplantation (HSCT). Yet a standard approach to diagnosis and treatment of ES remains elusive and has the potential to impact patient outcomes. A literature search was performed using the databases ProQuest Health, PubMed, Medline and Embase. Included studies were published in English from 2001‐2019 that reported on engraftment syndrome following HSCT. Articles were organized by study design, ES diagnostic criteria, symptom classification and treatment. The review consolidated an array of literature relating to all types of HSCT. Timing of ES onset, risk factors and outcomes were compared within the literature. Signs and symptoms of reported ES were collated to establish a concise set of diagnostic criteria that can provide rapid recognition. The use of a standard approach to ES diagnosis has the potential to improve patient outcomes and provide a uniform approach to future research.

show abstract

“…Pulmonary disease processes can occur at any time during transplant. Early etiologies can be from infections, pulmonary edema, or idiopathic pneumonia syndrome [7]. Later pulmonary manifestations can also be due to infection or bronchiolitis obliterans (BO), a progressive fibrotic process that can occur with or without other manifestations of chronic graft-versus-host disease (GVHD) [8].…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Impact and Complications Associated with Surgical Lung Biopsy after Allogeneic Hematopoietic Stem Cell Transplantation in Children

Dieffenbach

Madenci

Murphy

et al. 2019

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Hematopoietic stem cell transplantation (HSCT) in the pediatric population is associated with pulmonary complications in 25% of recipients. The role of surgical lung biopsy (SLB) remains unclear because of concerns about both the therapeutic impact and morbidity associated with the procedure. A retrospective review of consecutive allogeneic HSCT recipients at Dana-Farber and Boston Children's Hospital Cancer and Blood Disorders Center between 2006 and 2016 was performed. All recipients who underwent SLB during the study period were identified and charts reviewed for perioperative complications, histopathologic findings, and changes in therapy delivered. Pearson's chi-square test and Student's t-test (or appropriate nonparametric test) were used to evaluate the associations between perioperative complication and categorical and continuous variables, respectively. Five hundred fifty-five HSCTs were included, among which 48 SLBs (8.6%) were identified. Median follow-up time was 24 months (range, 0 to 139). Thirty-day postoperative morbidity was 16.7% and 30-day postoperative mortality 10.4% (n = 5). The overall 30-day postoperative complication rate (including mortality) was 20.8% (n = 10). No mortalities were directly attributable to SLB. Definitive diagnoses were identified in 70.8% of SLBs (n = 34), and therapeutic changes occurred in 79.2% (n = 38). Overall, 83.3% of SLBs (n = 40) either provided a diagnosis or led to a change in therapy. SLB has an acceptable risk of perioperative complications in this medically complicated and often severely ill population. In most HSCT patients, SLB aids in defining the etiology of pulmonary infiltrates and can inform therapeutic decisions in patients where noninvasive diagnostic modalities have failed to provide a definitive diagnosis.

show abstract

Noninfectious Acute Lung Injury Syndromes Early After Hematopoietic Stem Cell Transplantation

Cited by 35 publications

References 98 publications

Noninfectious pulmonary complications of haematopoietic stem cell transplantation

Noninfectious pulmonary complications of haematopoietic stem cell transplantation

Engraftment syndrome following hematopoietic stem cell transplant: A review of the literature

Therapeutic Impact and Complications Associated with Surgical Lung Biopsy after Allogeneic Hematopoietic Stem Cell Transplantation in Children

Contact Info

Product

Resources

About